Prognostic value of stromal cell‐derived factor 1 expression in patients with gastric cancer after surgical resection

Aberrant chemokine stromal cell‐derived factor 1 (SDF‐1) expression has been shown to be involved in the development and progression of various malignancies. Our present study aims to investigate the clinical and prognostic value of SDF‐1 expression and improve risk stratification in patients with gastric cancer. Peritumoral and intratumoral SDF‐1 levels were assessed in 220 retrospectively enrolled gastric cancer patients, and their relations with clinicopathological features and clinical outcomes were evaluated. A predictive nomogram was created to refine risk stratification for overall survival of gastric cancer patients. Compared with peritumor tissues, tumor tissues showed decreased SDF‐1 expression levels according to TNM stage progression in gastric cancer specimens. Peritumoral SDF‐1 expression correlated positively with tumor invasion depth and lymph node metastasis, whereas intratumoral SDF‐1 expression associated negatively with tumor size, tumor differentiation, tumor invasion depth, lymph node metastasis, and clinical TNM stage. Moreover, both low peritumoral SDF‐1 expression and high intratumoral SDF‐1 expression indicated favorable overall survival, and SDF‐1 risk derived from the peritumoral/intratumoral SDF‐1 expression signature could stratify prognosis of patients with gastric cancer. After backward elimination, SDF‐1 risk was identified as an independent prognostic factor for survival. Finally, a predictive nomogram was generated with identified independent prognosticators to assess patient survival at 3 and 5 years following surgery. Conclusively, SDF‐1 risk, an identified independent prognostic factor, could be developed into a nomogram with tumor invasion depth, lymph node involvement, and distant metastasis to refine predictive accuracy for survival in patients with gastric cancer after surgical resection.     

Significance of Thrombocytosis in Clinicopathologic Characteristics and Prognosis of Gastric Cancer

Purpose: We aimed to study the relationship between thrombocytosis and clinical features of gastric cancerfocussing on platelet counts and gastric cancer progression through different TNM stages. Methods: According to the normal range of platelet count in our institution, 1,596 patients were divided to two groups:a thrombocytosis group (120 patients, >400×1000/μL) and a control group (1,476 patients, ≤400×1000/μL). Results: The incidence of thrombocytosis was 7.5%. Higher platelet counts were observed in patients with older age, larger tumor size, deeper invasion, lymph node metastasis, distant metastasis and advanced TNM stage. In multivariate logistic regression, tumor size, depth of tumor invasion, lymph node metastasis and TNM stage were independent risk factors for thrombocytosis of gastric cancer patients. On prognostic analysis, age, tumorsize, tumor location, histologic type, depth of tumor invasion, lymph node metastasis, distant metastasis and TNM stage and platelet count were important factors. Tumor size, invasion depth, lymph node metastasis, TNM stage and the platelet count were independent prognostic factors. Conclusion: Thrombocytosis is associated with clinical features of gastric cancer patients and correlates with a poor prognosis.     

Prognostic Value of Tumor-Related Molecular Expression in Gastric Carcinoma

In order to identify reliable molecular markers for prognostic prediction in gastric carcinoma, we evaluated the expression of six molecular markers, namely bFGF, IGF-2, HGF, MMP-9, integrin β3 and uPA in gastric cancer. There was a significant correlation between the expression of these markers and the depth of tumor invasion, vessel invasion, lymph node and distant metastasis, TNM stage and microvessel density. The average survival time and 5-year survival rate of patients with positive expression of molecular markers was higher than those with negative expression. Multivariate analysis showed that abnormal expression of bFGF, MMP-9 and uPA, as well as depth of invasion, lymph node and distant metastasis and TNM stage were independently related to poor prognosis of gastric cancer. MMP-9, bFGF and uPA are potential candidates for development as clinically applicable molecular prognostic markers for gastric carcinoma, and may be effective therapeutic targets for the disease in the future.     

L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients

Background

L1 cell adhesion molecule (L1CAM) and epithelial cell adhesion molecule (EPCAM) have been implicated in the development and progression of gastric cancer. The present study investigated the clinical significance of L1CAM and EPCAM in the development, progression and prognosis of gastric cancer.

Methods

Expression of L1CAM and EPCAM were examined immunochemically in 601 clinicopathologically characterized gastric cancer cases.

Results

L1CAM protein was detected in 23.9% of human non-tumor mucosa samples. All samples expressed L1CAM protein at low levels. High expression of L1CAM protein was detected in 163 (27.1%) tumors. Expression of L1CAM correlated with age, tumor location, size of tumors, Lauren’s classification, depth of invasion, lymph node and distant metastases, regional lymph node stage, Tumor-Node-Metastasis (TNM) stage and prognosis. EPCAM protein was detected in 45.7% of human non-tumor mucosa samples. All samples expressed EPCAM protein at low levels. High expression of EPCAM protein was detected in 247 (41.1%) tumors. Expression of EPCAM correlated with age, tumor location, size of tumors, Lauren’s classification, depth of invasion, lymph node and distant metastases, regional lymph node stage, TNM stage and prognosis. Cumulative 5-year survival rates of patients with high expression of both L1CAM and EPCAM were significantly lower than in patients with low expression of both.

Conclusions

Expression of L1CAM and EPCAM in gastric cancer was significantly associated with lymph node and distant metastasis, and poor prognosis. L1CAM and EPCAM proteins could be useful markers to predict tumor progression and prognosis.     

nm23-H1和CD44V6在胃癌中的表达及其临床意义

目的探讨nm23-H1和CD44V6在胃癌的浸润和淋巴结转移过程中的作用机理及临床意义。方法用免疫组化LSAB方法检测nm23-H1和CD44V6蛋白在65例胃癌中的表达。结果nm23-H1的表达与胃癌的浸润、淋巴结转移和TNM分期呈负相关,与预后呈正相关。CD44V6的阳性表达率随胃癌浸润的加深而升高,与淋巴结转移和TNM分期呈正相关,CD44V6阳性者术后3年生存率低于阴性者(P<0.05)。结论nm23-H1和CD44V6的表达与胃癌的发生、发展和预后等密切相关,可作为判断胃癌预后的指标。     

YAP、VGLL4蛋白在胃癌组织中的表达及对侵袭和转移的影响

目的:探讨YAP、VGLL4蛋白在胃癌组织中的表达对侵袭和转移的影响。方法:采用免疫组织化学SP法及Western blot法检测胃癌组织及癌旁组织中YAP、VGLL4蛋白的表达情况,分析其表达与胃癌临床病理参数的关系,从而判断其对侵袭和转移的影响。结果:YAP、VGLL4的阳性表达主要位于细胞核,少数在胞浆表达。YAP在胃癌组织中较癌旁组织表达增加,且与患者年龄、肿瘤分化、浸润深度、淋巴结转移和TNM分期呈正相关。VGLL4蛋白在胃癌组织中较癌旁组织表达减少,且与浸润深度、淋巴结转移和TNM分期呈负相关。结论:YAP蛋白在胃癌组织中表达升高,与肿瘤发展和恶性程度呈正相关,肿瘤容易发生侵袭和转移,VGLL4在胃癌组织中呈明显下降趋势,且与肿瘤发展和恶性程度呈负相关。     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

LGR5和E-cadherin在胃癌组织中的表达及临床意义

目的 探讨富含亮氨酸重复序列G蛋白偶联受体5（leucine-rich repeat-containing G protein-coupled receptor 5,LGR5）和 E-钙粘蛋白（E-cadherin）在胃癌组织中的表达及其临床意义。方法 收集2014年8月—2016年5月在中南大学湘雅医学院附属株洲医院手术切除的115例胃癌组织及相应20例癌旁正常组织标本。采用免疫组化SP法检测LGR5和E-cadherin的表达水平,分析LGR5与E-cadherin表达的相关性及其与胃癌患者临床病理特征和预后的关系。结果 LGR5和E-cadherin在胃癌组织中阳性表达率分别为62.6%和53.9%,与癌旁正常组织相比,差异有统计学意义（P<0.05）;LGR5和E-cadherin表达均与肿瘤大小、TNM分期、浸润深度、淋巴结转移及远处转移有关（P<0.05）;相关分析显示,LGR5与E-cadherin表达呈负相关（r=-0.318,P=0.001）。LGR5阴性表达患者的1年、3年总生存率高于阳性表达患者（P<0.001）,E-cadherin阳性表达患者的1年、3年总生存率亦高于阴性表达患者（P<0.001）;多因素Cox回归分析显示,TNM分期Ⅲ~Ⅳ期、淋巴结转移、远处转移、LGR5表达阳性及E-cadherin表达阴性是影响胃癌患者预后的独立危险因素（P<0.05）。结论 LGR5在胃癌组织中高表达而E-cadherin表达缺失,可能导致胃癌的发生发展及不良预后。     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.     

胃癌中CD147和上皮型钙黏蛋白的表达及意义

目的 研究胃癌组织中CD147和上皮型钙黏蛋白(E-cadherin)的表达情况及其与胃癌临床病理特征的关系.方法 制备组织芯片,应用原位杂交和免疫组化技术检测220例胃癌组织和31例正常胃黏膜中CD147和E-cadherin的表达情况.结果 CD147mRNA、E-cadherin mRNA和E-cadherin蛋白在胃癌组织中的阳性表达率分别是50.5%、17.7%和15.5%,CD147与E-cadherin表达呈负相关,CD147 mRNA的表达与胃癌的肿瘤大小、TNM分期、浸润深度、脉管侵犯、淋巴结转移和远处转移相关;E-cadherin mBNA的表达与胃癌的TNM分期、浸润深度和脉管侵犯相关;E-cadherin蛋白的表达与肿瘤大小、TNM分期和脉管侵犯相关.CD147 mRNA阳性表达患者的平均生存时间和5年生存率明显低于阴性者,而E-cadherin mRNA和蛋白阳性者的平均生存时间和5年生存率明显高于阴性者.结论 胃癌组织中,CD147表达上调,E-cadherin表达下调,且二者呈负相关;联合检测胃癌组织中CD147和E-cadherin的表达情况,可预测胃癌的浸润和转移,对指导临床治疗及预后评估有重要意义.